Gyn-Onc
Gyn-Onc
Advertisement
Laura LitwinGyn-Onc | November 21, 2024
The study found that patients with cervical cancer may be at risk for malnutrition if treated with chemoradiotherapy.
Read More
Laura LitwinGyn-Onc | November 15, 2024
Research on follow-up adherence in patients with cervical cancer shows how nurse liaisons can help reduce patient anxiety.
Laura LitwinGyn-Onc | November 13, 2024
The study explores the effects of a Saturday pap smear clinic on improving access to cervical cancer screening for women.
Laura LitwinGyn-Onc | November 6, 2024
Socioeconomic barriers and access to palliative chemotherapy affect survival outcomes for patients with cervical cancer.
Leah LawrenceGyn-Onc | September 27, 2024
Women with deep infiltrating endometriosis and/or ovarian endometriosis had the highest risk for ovarian cancer.
Leah LawrenceGyn-Onc | September 27, 2024
Learn how a team implemented pre-screening and fast-track strategies to increase clinical trial enrollment in these patients.
Leah LawrenceGyn-Onc | September 27, 2024
New research highlights the importance of using appropriate patient-reported outcome measures for these patients.
Leah LawrenceGyn-Onc | September 26, 2024
The phase III, placebo-controlled AtTEnd trial included 551 patients, with 23% in each arm having dMMR tumors.
Leah LawrenceGyn-Onc | September 26, 2024
Symptom-triggered testing resulted in 1 in 4 women being diagnosed with high-grade serous ovarian cancer at an early stage.
Leah LawrenceGyn-Onc | September 26, 2024
Researchers identified 6 risk factors for urinary retention that are critical for nurses to be aware of in these patients.
Katie KoskoGyn-Onc | September 25, 2024
A team of researchers evaluated the Neuman model of care in the perioperative setting for patients with endometrial cancer.
Leah LawrenceGyn-Onc | September 25, 2024
A long-term study points to the importance of evaluating risks and benefits with estrogen versus progesterone with estrogen.
Leah LawrenceGyn-Onc | September 26, 2024
Patients receiving the antibody-drug conjugate showed a 30% reduction in the risk of death compared with chemotherapy.
Leah LawrenceGyn-Onc | September 25, 2024
A new study is shedding light on post-treatment experiences, with many saying they felt they were "left to themselves."
Katie KoskoGyn-Onc | September 24, 2024
Learn about the link between muscle quality and the risk of postoperative complications in these patients.
Katie KoskoGyn-Onc | September 24, 2024
Learn how the BOLSTER nurse-led telehealth intervention can help patients with gynecologic cancers manage this condition.
Katie KoskoGyn-Onc | September 16, 2024
An interim analysis of part 2 of the RUBY trial showed that dostarlimab plus chemotherapy lowered the risk of death by 31%.
Katie KoskoGyn-Onc | September 16, 2024
Learn how medical history, perceived physician-patient communication, and perceived social support impact patients.
Katie KoskoGyn-Onc | September 7, 2024
Approximately half of patients with gynecologic malignancies experience financial toxicity.
Cecilia BrownGyn-Onc | August 15, 2024
The expanded approval is based upon results from part 1 of the phase III RUBY trial.
Advertisement
Advertisement
Advertisement